European drug regulators recently created a pathway for generic ersions of biotech drugs to come to market.
欧洲药物管理部门近来开创了一条允许非专利生物技术药物进入市场的通道。
European drug regulators recently created a pathway for generic versions of biotech drugs to come to market.
欧洲药物管理部门近来开创了一条允许非专利生物技术药物进入市场的通道。
Last year biotech drugs accounted for 70% of the increase in pharmaceutical costs in America, according to Medco, a drug-plan manager.
据药品计划管理公司Medco（中文名：美可）称，去年生物技术药品占美国药品费用增长额的70%。
A division of deerfield illinois-based Baxter healthcare corp based in glendale California is another biotech pioneer. it introduced the first biotech drug for hemophilia a in1992.
位于伊利诺斯州鹿园的贝克斯特康复公司在加州的格林·代尔设有分部。这个分公司是生物技术方面的又一个先锋，于1992年推出第一种治疗a型血友病的生物技术药。
Others are teaming up with big energyfirms, in much the same way that biotech companies with a promising drug areoften taken under the wing of a large pharmaceutical company.
其余的与大能源公司合作，大家几乎都有着一种前途光明的药品，通常在大制药公司的羽翼下。
He cites in evidence a drug trial by Amgen, a biotech giant, where the researchers concluded that the drug was not effective.
Grove博士举出了这样的一个例子：那是一个由生物技术界的巨头——安进公司所进行的一项药品实验。在这项实验里，研究人员总结道，该药品并不有效。
Research funded by the multiple myeloma Re — search Foundation at a small biotech led to a promising new drug for multiple myeloma, a cancer of plasma cells in bones.
MultipleMyeloma研究基金会资助了一家小型生物科技企业的研究，发现了一种很有前途的新药，能够治疗多发性骨髓瘤，一种骨头中原生质细胞的癌症。
Research funded by the Multiple MyelomaRe--search Foundation at a small biotech led to a promising new drug formultiple myeloma, a cancer of plasma cells in bones.
MultipleMyeloma研究基金会资助了一家小型生物科技企业的研究，发现了一种很有前途的新药，能够治疗多发性骨髓瘤，一种骨头中原生质细胞的癌症。
A breakthrough came more than a decade ago when Genentech, a Californian biotech firm, launched a drug that attacks breast-cancer cells with too much of a certain protein, HER2.
十多年前就取得了重大进展，一个加州的生物科技公司Genentech(中文名：基因泰克)发行了一种药物，这种药物攻击蛋白质HER2(中文名：人表皮生长因子受体- 2)含量过多的乳腺癌细胞。
A list should be provided of physicochemical and other relevant properties of the drug substance, including biological activity for Biotech.
应提供原料药的物理化学的或其它相关的性质的列表，包括生物技术产品的生物活性。
If you are an emerging biotech designing pivotal trials for the drug candidate that is going to make or break you, you should aim to power the trials at 90 percent.
如果你是一家刚起步的生物公司，正在为攸关公司生死存亡的一个候选药设计关键实验，那么你的目标效强应该是90%。
If you are an emerging biotech designing pivotal trials for the drug candidate that is going to make or break you, you should aim to power the trials at 90 percent.
如果你是一家刚起步的生物公司，正在为攸关公司生死存亡的一个候选药设计关键实验，那么你的目标效强应该是90%。
应用推荐